Effect of inhalation drug therapy on inflammatory factors and quality of life on stable chronic obstructive pulmonary disease.

Objective: To investigate the clinical efficacy of inhaled triple therapy in the treatment of stable chronic obstructive pulmonary disease (COPD).

Methods: This is a clinical comparative study. A total of 80 patients with COPD admitted to the First People's Hospital of Suining City from June 2020 to June 2023 were included and randomly divided into the study (conventional COPD treatment + inhaled triple therapy) and control (conventional COPD treatment) groups. The clinical efficacy of inhaled triple therapy and adverse reactions of the two groups to the treatment were observed. Clinical efficacy was assessed through changes in pulmonary function indexes, and comparisons of T lymphocyte subsets and serum inflammatory markers were conducted. In addition, St George's Respiratory Questionnaire (SGRQ) was employed for the quality-of-life assessment.

Results: The study group showed a significantly higher total efficacy than the control group (P < 0.05), with no significant difference in terms of adverse reactions between them (P > 0.05). After treatment, the study group showed better improvement in pulmonary function indexes, such as forced expiratory volume in one second (FEV₁), FEV₁ as a percentage of the expected value, forced vital capacity (FVC) and FEV₁/FVC, compared with the control group (all P < 0.05). In addition, the study group presented higher levels of T lymphocyte subsets CD3⁺, CD4⁺ and CD4⁺/CD8⁺ than the control group(all P < 0.05). After treatment, the levels of inflammatory markers tumour necrosis factor-α, leukotriene B4 LTB4 and interleukin-6 in the study group decreased more than those in the control group (all P < 0.05). Moreover, the study group attained a lower SGRQ score than the control group (all P < 0.05).

Conclusion: Triple inhalants further improve the clinical efficacy of the treatment of COPD.